Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund News: Alex Denner, Steven Tananbaum, Bill Ackman

Page 1 of 2

Ariad Pharma CEO ‘Retires’ in Settlement With Activist Hedge Fund (The Street)
Ariad Pharmaceuticals founder and CEO Harvey Berger is exiting the struggling cancer drug company in a settlement with Sarissa Capital, the activist hedge fund led by Alex Denner, the company said Wednesday. Denner’s fund, which owns almost 7% of Ariad, started a proxy fight last February to wrest control of the board and force Berger’s ouster. Ariad shares tumbled in 2013 because safety problems tied to the company’s leukemia drug Iclusig led to restrictions on its use and cut into sales growth significantly.

Alex Denner Sarissa Capital

Vulture Circles Indebted Tech Companies (CNBC)
Silicon Valley may still be chasing the proverbial unicorns of technology, but at least one big Wall Street investor is thinking more like a vulture. Steve Tananbaum, a leading investor in the bonds of troubled companies, said the technology arena is one of the most interesting opportunities in the market today, given the high debt load carried by mediocre companies. “One sector that hasn’t gotten as much attention in the press but we think is very vulnerable is the technology sector,” the chief investment officer of $23 billion GoldenTree Asset Management said Tuesday at the Milken Institute Global Conference in Los Angeles.

Ackman Activism Deja Vu Evoked as Railroad Options Surge (Bloomberg)
Bullish options on railroad stocks including CSX Corp. have surged amid speculation that an activist investor is building a stake in one of the companies. CSX’s stock jumped 11 percent last week as trading volume ballooned to more than double the five-year average. To UBS AG analyst Thomas Wadewitz, the trading was reminiscent of what occurred with Canadian Pacific Railway Ltd. when billionaire hedge-fund manager William Ackman was buying shares prior to a proxy fight that led to a boardroom coup.

Mayer Brown’s Brian Nolan On Strategy Behind Drug Patent Challenges (Reuters)
Prominent hedge fund manager Kyle Bass‘ threat last January to knock out big pharmaceutical companies’ patents has not proved idle. In recent months, his Coalition for Affordable Drugs has filed petitions for inter partes review of nine drug patents at the U.S. Patent and Trademark Office. The review process was part of a series of reforms brought about by the 2011 America Invents Act, making it faster and easier to challenge patent validity outside of federal courts, and allowing petitions by third parties.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!